Zevra Therapeutics Inc Ordinary Shares ZVRA 深 沪
已收盘 08-29 16:00:00 美东时间
9.07
-0.230
-2.47%
华盛通- 最 高9.39
- 今 开9.30
- 成交量 96.65万股
- 最 低 8.97
- 昨 收 9.30
- 总市值 4.96亿
- 52周最高 13.16
- 市盈率 静 --
- 换手率 1.77%
- 52周最低 6.19
- 委 比 -20.08%
- 总股本 5467.96万
- 历史最高 418.40
- 量 比 1.03
- 振 幅 4.52%
- 历史最低 0.206
- 每 手 1
- 风险率 1.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Zevra Therapeutics To Present Four Posters On MIPLYFFA At ICIEM 2025
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced four posters on MIPLYFFA® (MY-PLY-FAH)
08-28 19:32
Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)
Zevra Therapeutics will present four posters on MIPLYFFA (arimoclomol), its approved therapy for Niemann-Pick disease type C (NPC), at the International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan. The posters highlight MIPLYFFA's mechanism of action, safety, efficacy, and real-world outcomes, including a pediatric substudy and a prespecified efficacy analysis. One poster received a Best Poster award for its focus on MIPLYFFA'...
08-28 11:30
Zevra Therapeutics to Participate at Upcoming Investor Conferences in September
Zevra Therapeutics announced that its leadership team will attend two healthcare conferences in September: the Cantor Global Healthcare Conference on Sept. 3 and the H.C. Wainwright Annual Global Investment Conference on Sept. 8. They will also hold one-on-one meetings with attendees. The company specializes in developing therapies for rare diseases and aims to address unmet medical needs. (168 characters)
08-26 11:30
Zevra Therapeutics gains amid takeover speculation
Zevra Therapeutics (NASDAQ:ZVRA) rose 3% amid takeover speculation. There's talk that Zevra (NASDAQ:ZVRA) may have attracted takeover interest, according to traders, who cited a Betaville "uncooked" ...
08-21 22:55
Zevra治疗公司营收增长26%
罕见病药物开发商Zevra治疗公司（ZVRA）报告营收增长26%并完成1.5亿美元优先审评券（PRV）出售，显著增强了资产负债表实力。该公司正着力扩大市场覆...
08-13 22:36
JMP Securities Maintains Market Outperform on Zevra Therapeutics, Lowers Price Target to $18
JMP Securities analyst Jason N. Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform and lowers the price target from $19 to $18.
08-13 22:27
Zevra Therapeutics Q2 EPS $1.24 Beats $1.13 Estimate, Sales $25.90M Beat $22.49M Estimate
Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $1.24 per share which beat the analyst consensus estimate of $1.13 by 10.22 percent. This is a 358.33 percent increase over losses of $(0.48) per share from
08-13 04:09
Here are the major earnings after the close Tuesday
Major earnings expected after the bell on Tuesday include: CoreWeave (CRWV) Inovio Pharmaceuticals (INO) Luminar Technologies (LAZR) Lumentum Holdings (LITE) Gladstone Investment Corporation (GAIN) Ot...
08-12 22:00
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
Zevra Therapeutics announced that its executives will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference in Boston on August 13, 2025, at 1:00 p.m. ET. Management will also meet with conference attendees, and a live webcast will be available on Zevra’s Investor Relations website. The company specializes in developing therapies for rare diseases and aims to bring life-changing treatments to patients through data-...
08-06 11:30
